Aurobindo Pharma gets six observations from USFDA for Unit VII; Stock sheds 2%

11 May 2022 , 09:22 AM

The United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma Ltd’s Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, from May 02-10, 2022.

“At the end of the inspection, we have been issued a ‘Form 483’ with six observations”, said pharma major in a regulatory filing on Tuesday.

Further, the Company will respond to the US FDA within the stipulated timeline and work closely with US FDA to close the observations.

At around 9:22 AM, Aurobindo Pharma was trading at Rs591.15 per piece lower by 1.97% on the BSE.